β AdR and muscarinic AChR autoantibodies are elevated in a subset of patients with CFS.
High autoantibodies correlate with elevated IgG1–3, TPO and ANA antibodies and T cell activation.
In patients responding to rituximab high pretreatment autoantibodies declined after treatment.